NASDAQ:NERV Minerva Neurosciences Q2 2026 Earnings Results & Report $2.89 -0.29 (-9.12%) Closing price 04:00 PM EasternExtended Trading$2.88 -0.01 (-0.17%) As of 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Minerva Neurosciences beat analyst earnings expectations in its Q2 2026 results, released August 7, 2026. The company reported EPS of -$0.14 versus the -$0.1933 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 7, 2026TimeBefore Market OpensConference Call7:00 AM ET Minerva Neurosciences EPS ResultsActual EPS-$0.14Consensus EPS -$0.1933Beat/MissBeat by +$0.0533One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersMinerva Neurosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsMinerva Neurosciences' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 5, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Minerva Neurosciences Q2 2026 Earnings FAQ Did Minerva Neurosciences beat earnings estimates for Q2 2026? Minerva Neurosciences (NASDAQ:NERV) reported earnings of -$0.14 per share for Q2 2026, beating the consensus estimate of -$0.1933. The report was announced on Friday, August 7, 2026. When is Minerva Neurosciences' next earnings date? Minerva Neurosciences' next earnings date is estimated for Wednesday, November 4, 2026. MarketBeat tracks confirmed and estimated earnings dates for Minerva Neurosciences on the company's earnings history page. Minerva Neurosciences Earnings HeadlinesMinerva Neurosciences, Inc (NASDAQ:NERV) Stock Now Rated "Reduce" by Wall Street AnalystsOctober 8, 2026 | americanbankingnews.comMinerva Neurosciences (NASDAQ:NERV) Stock Price Crosses Below Two Hundred Day Moving Average - Should You Sell?October 2, 2026 | americanbankingnews.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.October 12 at 1:00 AM | Weiss Ratings (Ad)Minerva Neurosciences to Participate in Two Upcoming Investor ConferencesAugust 28, 2026 | globenewswire.comMinerva Neurosciences Provides Second Quarter 2026 Financial Results and Business UpdatesAugust 7, 2026 | globenewswire.comMinerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline ProgramsJune 1, 2026 | globenewswire.comSee More Minerva Neurosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Minerva Neurosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Minerva Neurosciences and other key companies, straight to your email. Email Address About Minerva NeurosciencesMinerva Neurosciences (NASDAQ:NERV). is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. The company’s research activities have centered on conditions including schizophrenia, major depressive disorder and other neuropsychiatric diseases with significant unmet medical needs. Minerva’s lead investigational product has been roluperidone, formerly known as MIN-101, an orally administered compound studied as a potential treatment for negative symptoms of schizophrenia. The company has also been involved in the development of other central nervous system drug candidates, including treatments designed to influence serotonin, sigma and orexin receptor pathways. Founded in 2007 and headquartered in Waltham, Massachusetts, Minerva has conducted clinical development activities in the United States and Europe. Its programs have primarily been advanced through clinical trials and collaborations with pharmaceutical companies and research organizations. As a development-stage biotechnology company, Minerva’s operations and product portfolio have historically focused on advancing investigational therapies rather than marketing an established commercial product line.View Minerva Neurosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Retail Picks to Watch as the Holiday Shopping Season NearsMarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsC.H. Robinson Bets Its AI Story on RXO—But the Market Isn't SoldApplied Digital’s Hidden Moat Could Unlock Massive Upside Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
